Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Fabiani

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Blood Cancer Journal|April 22, 2017
EZH2 alterations in follicular lymphoma: biological and clinical correlationsS Huet, L Xerri, B Tesson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA groupE Tchernonog, P Faurie, P Coppo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2012
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)N Ketterer, B Coiffier, C Thieblemont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trialT Petrella, C Copie-Bergman, J Brière, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Blood Cancer Journal|April 22, 2017
EZH2 alterations in follicular lymphoma: biological and clinical correlationsS Huet, L Xerri, B Tesson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA groupE Tchernonog, P Faurie, P Coppo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2012
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)N Ketterer, B Coiffier, C Thieblemont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trialT Petrella, C Copie-Bergman, J Brière, et al.
Pageof 4